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Several candidates for a vaccine against Burkholderia pseu-
domallei, the causal bacterium of melioidosis, have been 
developed, and a rational approach is now needed to select 
and advance candidates for testing in relevant nonhuman 
primate models and in human clinical trials. Development 
of such a vaccine was the topic of a meeting in the United 
Kingdom in March 2014 attended by international candidate 
vaccine developers, researchers, and government health 
officials. The focus of the meeting was advancement of 
vaccines for prevention of natural infection, rather than for 
protection from the organism’s known potential for use as 
a biological weapon. A direct comparison of candidate vac-
cines in well-characterized mouse models was proposed. 
Knowledge gaps requiring further research were identified. 
Recommendations were made to accelerate the develop-
ment of an effective vaccine against melioidosis.
Melioidosis vaccines are urgently needed for both pub-lic health and biodefense purposes. The bacterium 
Burkholderia pseudomallei, the causal organism of meli-
oidosis, was designated as a category B select agent by the 
US Centers for Disease Control and Prevention (CDC) and 
as a Tier 1 select agent by National Select Agent Registry 
(NASR), a joint program of the CDC and the Animal and 
Plant Health Inspection Service of the US Department of 
Agriculture. These designations have led to considerable 
research funding to develop a melioidosis vaccine (1,2). 
The potential for humans to be infected with B. pseudomal-
lei by inhalation, the low infective dose by this route, and 
difficulties associated with diagnosis and treatment have 
led to this organism being considered to be at high risk for 
deliberate misuse as a weapon (3,4,5). 
B. pseudomallei is readily isolated from soil and water 
in many tropical areas across Southeast Asia, the Indian sub-
continent, northern Australia, and parts of South America 
and the Caribbean (6). In these areas, melioidosis can be 
naturally acquired by skin inoculation, ingestion, and inha-
lation of environmental B. pseudomallei. In northeast Thai-
land, melioidosis kills an estimated >1,000 persons per year 
(7). A vaccine could be cost-effective for the prevention of 
melioidosis among populations at high risk for infection by 
B. pseudomallei, such as persons who have diabetes (8).
Establishing a process for selecting, assessing, and 
advancing potential vaccine candidates is a critical issue 
for the melioidosis research community. Several vaccine 
candidates have been shown to provide partial protection 
in murine models of infection (8–10), but none have been 
tested to date in nonhuman primates (NHP) or humans. 
Possible candidates include live attenuated, whole-cell 
killed, subunit, glycoconjugate, outer membrane vesicle, 
plasmid DNA, and dendritic cell vaccines (8); possible can-
didates and candidate developments have been systemati-
cally reviewed and reported (8–10). A notable lack of stan-
dardization of protocols has resulted in variability in the 
animal models used (mice [BALB/c, C57BL/6, and Porton] 
and Syrian hamster); route of inoculation (intraperitoneal, 
intravenous, intranasal, intradermal, and subcutaneous); 
challenge strains (K96243, 1026b, 576, NCTC13392, 
NCTC4845, and NCTC13179); route of B. pseudomallei 
challenge (intraperitoneal, intravenous, aerosol inhalation, 
and intranasal); challenge dose; and duration of the follow-
up period for assessing mortality rates among acute and 
chronic challenge models (5 days to 5 months) (8–10). As 
a result of the lack of consistency in use of specific meth-
ods on specific models, it is not possible to determine the 
comparative efficacy of different vaccine candidates. This 
inconsistency prevents researchers and officials in sponsor-
ing and funding agencies from deciding which candidates 
should be advanced to NHP models. Recognizing these 
problems, our objectives were to assemble an expert group 
and arrive at consensus opinions and recommendations on 
candidate vaccines and animal models based on currently 
available evidence (8–10).
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The Working Group
The Steering Group on Melioidosis Vaccine Development 
(SGMVD) was conceptualized during attendance of the 
VIIth World Melioidosis Congress (WMC), held in Bang-
kok, Thailand in September 2013. A questionnaire was 
initially composed by D.L. and S.J.P. based on perceived 
uncertainties and was intended to generate discussions re-
garding these barriers to progress (online Technical Ap-
pendix, http://wwwnc.cdc.gov/EID/article/21/6/14-1480-
Techapp1.pdf). The questionnaire was circulated to all 
members of the steering group in October 2013. Responses 
were collated and recirculated to all members during Janu-
ary 2014. All members of SGMVD returned the question-
naire. Then, additional experts from the United Kingdom 
and United States were invited to a face-to-face meeting of 
the steering group, which was held in March 2014 at Pub-
lic Health England (PHE), Porton Down, United Kingdom. 
All members except Bart Currie attended the face-to-face 
meeting. Recommendations from the SGMVD were circu-
lated for approval. All members agreed with the consensus 
opinions of the meeting attendees.
Development of Melioidosis Vaccines to  
Prevent Natural Infection Versus Biodefense Use
The development process of a melioidosis vaccine that 
prevents naturally acquired infection is likely to be differ-
ent than that for biodefense purposes (Table). This differ-
ence is because a biodefense vaccine is intended to protect 
healthy persons from inhalational inoculation, whereas a 
vaccine against natural infection will be required to protect 
immune-compromised hosts, such as persons with diabe-
tes, who comprise the highest risk group and are most of-
ten infected by skin inoculation (8). Therefore, the route 
of challenge in animal models should differ: inhalation 
should be the focus for biodefense vaccine development, 
and subcutaneous inoculation for natural infection vaccine 
development. It is also important to consider whether dia-
betic mouse models should be included for the evaluation 
of public health vaccines, and if so, which of the available 
diabetic mouse models best reflects the increased suscep-
tibility of the at-risk human population. An additional 
consideration is whether postexposure prophylaxis with 
antimicrobial drugs should be included in models for bio-
defense vaccines. Sharing of information between different 
groups would enhance progress. Because the development 
of biodefense vaccines and therapeutics is already support-
ed by other groups (e.g., Defense Threat Reduction Agen-
cy, National Institute of Allergy and Infectious Disease, 
and Biomedical Advanced Research and Development Au-
thority [BARDA]), this process was not discussed further 
by the group (8–11). The SGMVD agreed to focus further 
discussions on melioidosis vaccines that prevent naturally 
acquired infection.
Potential Use of Melioidosis Vaccines to Prevent 
Natural Infection in Melioidosis-Endemic Areas
During a discussion of needs for vaccines against natural-
ly acquired melioidosis, steering group member Charung 
Muangchana, director of National Vaccine Institute (NVI), 
Ministry of Public Health, Thailand, supported the pub-
lic health need for a melioidosis vaccine in Thailand. The 
point was made that no specific exclusion criteria would be 
proposed at the outset by NVI; for example, killed whole-
cell vaccines should not be excluded as a potential meli-
oidosis vaccine to be used for public health purposes in 
Thailand. A killed whole-cell vaccine could be considered 
if it passed phases I, II, and III clinical studies; had minimal 
side effects; and proved to be a cost-effective intervention 
in Thailand.
None of the candidate vaccines tested to date have 
provided sterilizing immunity, but it was proposed dur-
ing discussion that this should not be a barrier to using the 
best candidates in trials using NHP models. A melioidosis 
vaccine could be a cost-effective intervention for public 
health in areas to which melioidosis is endemic even if it 
only provided partial protection, resulting in reduction in 
disease severity and death rates among infected persons 
(8). For example, a melioidosis vaccine that reduced the 
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Table. Comparison of potential usage and animal models required for development of vaccines against naturally acquired melioidosis 
versus melioidosis vaccines for biodefense purposes* 
Vaccine characteristics 
Vaccines against naturally acquired 
melioidosis 
Melioidosis vaccines for 
biodefense purposes 
Target population   
 Character Persons with diabetes mellitus Healthy persons 
 Route of exposure Skin inoculation Inhalation 
Potential use of vaccine   
 Prophylaxis Yes Yes 
 Prophylaxis plus postexposure antimicrobial drug 
administration 
Yes* Yes† 
Animal models   
 Addition of diabetic mouse model Required Not required 
 Route of Burkholderia pseudomallei challenge Subcutaneous Inhalation 
 Nonhuman primate model Required Required 
*Administration of antimicrobial drugs after symptoms occur. 
†Administration of antimicrobial drugs after release. 
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incidence of melioidosis by 25%, reduced the case-fatality 
rate by 25%, provided protection for 3 years, and cost <100 
Thai Baht (≈$3 US) per course would be cost effective for a 
high-risk population in Thailand (estimated for population 
of persons who have diabetes, at a baseline annual inci-
dence rate of 150 cases per 100,000 persons per year, and a 
fatality rate of 40%) (8).
Process of Candidate Selection
The SGMVD recommended that the approach used to se-
lect, develop, and clinically evaluate tuberculosis (TB) vac-
cine candidates (12) be used as an example for a gating 
process for melioidosis candidate selection, because the 
challenges of vaccine development for TB and melioido-
sis are similar. No melioidosis vaccine has been tested in 
humans, and much could be learned from the TB vaccine 
testing process. The SGMVD agreed that a head-to-head 
comparison of candidate vaccines in standardized mouse 
models would support decision making by developers, 
sponsors, funders, and policy makers concerning the choice 
of candidate vaccine(s) advanced for testing in NHP mod-
els. To reduce any potential bias in candidate selection and 
conflicts of interest, SGMVD agreed that the head-to-head 
comparison should be performed in an institution that is 
independent of the vaccine developer. The gateway system 
and background information requested is similar to those 
features in the process of candidate selection of other vac-
cines (12). The candidate vaccine developer will also be 
responsible for the preparation of a trial lot to be tested at 
an independent institute (12). These processes are similar 
to that being conducted for TB vaccine candidate evalua-
tion (12).
The SGMVD noted that the information obtained from 
the head-to-head mouse model may not necessarily reflect 
the outcome that will be seen in a NHP model and eventu-
ally in human clinical trials. The purpose of using a combi-
nation of mouse and NHP models is to carefully select the 
optimal candidate vaccines for future clinical studies.
Standardized Mouse Models for Head-to-
Head Vaccine Candidate Comparison
Mouse Models
The SGMVD recommended that 2 mouse models (BALB/c 
and C57BL/6) be used for the head-to-head candidate vac-
cine assessment. These models were selected because they 
exhibit differential susceptibilities to B. pseudomallei in-
fection: C57BL/6 mice are more resistant (13,14). The 
evaluation should focus on protection from the acute stage 
of infection in both mouse models, reflecting the need to 
protect humans from rapidly fatal disease.
The SGMVD recommended that a diabetic mouse 
model should also be considered for use during the head-
to-head vaccine assessment. However, inherent problems 
were recognized, and a specific diabetic mouse model was 
not selected because of the current paucity of information 
on melioidosis in diabetic mouse models.
Formulas, Dosages, and Routes of Immunization
The SGMVD agreed that the production of the candidate 
vaccine, formulation, adjuvants used, toxicity, immuno-
genicity, recommendations for dosage, and routes of im-
munization are the responsibility of the developers. During 
the head-to-head comparison, the study institute should ad-
minister the candidate vaccine according to the guidelines 
provided by the developers.
Control Groups
The SGMVD recommended the use of 2 control groups 
in each head-to-head comparison: a negative-control non-
vaccinated group and a positive-control immunized group. 
The nonvaccinated group acts as a control for mortality 
outcome. The positive-control immunized group provides 
a benchmark for partial protection of a known vaccine 
candidate. The live attenuated mutant B. pseudomallei 
ilvI (commonly referred to as 2D2) is proposed as a posi-
tive control for the positive-control immunized group on 
the basis of high efficacy of 2D2 (15,16). This method has 
been tested in 2 independent laboratories in the United 
Kingdom (15,16), is effective in both genetically suscep-
tible (BALB/c) and resistant (C57BL/6) mouse strains, and 
is one of the most protective vaccines to be tested in the 
Burkholderia research field. It is easy to prepare as a stan-
dardized batch reagent (albeit under biosafety level 3 con-
ditions) for use as a reference for the effectiveness of other 
vaccine candidates. Although this method has not been 
tested for efficacy against a wide variety of B. pseudomal-
lei strains, it would be predicted to provide cross-protection 
on the basis that it is a live attenuated vaccine and will be 
expressing a range of antigens in the host. Confirming this 
efficacy against a chosen panel of approved B. pseudomal-
lei challenge strains represents a crucial and feasible first 
step for its inclusion as a reference standard in future vac-
cine development programs.
Challenge Strains of B. pseudomallei
The SGMVD proposed the use of 2 or 3 bacterial strains 
selected from a standard set of B. pseudomallei isolates 
characterized and recommended by BARDA for head-
to-head vaccine candidate comparisons, rather than a 
single randomly selected strain (11). This choice was 
made because there is clear evidence for strain-to-strain 
variation in virulence of B. pseudomallei, which can be 
further confounded by the number of strain passages and 
quality of bacterial storage. Six strains are recommended 
for initial consideration: MSHR668, MSHR305, 1026b, 
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 21, No. 6, June 2015 e3
ONLINE REPORT
1106a, K96243, and 406a. Each of the 6 strains prepared 
by BARDA has extensive and complete information, 
including source, passage history, virulence, genotype, 
and phenotype, and all are available from BARDA (11). 
Refining the recommendation for a subset of these 6 
strains could be made after more data from mouse models 
are available.
Challenge Route of B. pseudomallei
To replicate the most common route of natural melioido-
sis infection in humans, the SGMVD suggested that the 
subcutaneous route be used for the challenge dose of B. 
pseudomallei. Current knowledge on mouse models chal-
lenged via the subcutaneous route of B. pseudomallei is 
limited (17), and further studies are required to provide 
baseline data. No vaccine candidate to date has been evalu-
ated for efficacy against subcutaneous inoculation with B. 
pseudomallei (8–10). The SGMVD proposed that baseline 
information should be generated for each of the 6 strains 
recommended by BARDA in BALB/c and C57BL/6 mice 
by using the subcutaneous route.
Challenge Dose of B. pseudomallei
Because the aim of the head-to-head comparison is to 
compare the efficacy between >2 vaccine candidates, the 
SGMVD proposed that the challenge dose of B. pseudom-
allei be adjusted so that all animals in the negative-control 
nonvaccinated group reach humane euthanasia endpoints 
at 7–14 days postchallenge. If the challenge dose of B. 
pseudomallei is too high, both groups could reach eutha-
nasia endpoints too quickly, and the protective efficacy in 
vaccinated groups may not be evident. This practice was 
observed in a study evaluating vaccine candidates in pro-
tection against airborne challenge, in which all animals in 
the negative-control (nonvaccinated) group died by day 
4 and all animals in the vaccinated groups died by day 5 
(18). Alternatively, if the challenge dose of B. pseudomal-
lei is too low, only a fraction of the nonvaccinated control 
groups may reach euthanasia endpoints, and the power to 
detect protective efficacy in vaccinated groups will be very 
low in a survival analysis. This result has been commonly 
observed (8–10) when bacterial burden of major organs has 
been used as a secondary endpoint to evaluate protection 
from subclinical infection.
Timing of Challenge
It is essential that the B. pseudomallei challenge be done no 
sooner than 4 weeks after the last dose of vaccine to enable 
residual innate immune responses to quiesce. Otherwise, 
the survival benefit observed in mouse models could be 
overestimated because of the residual short-term innate im-
mune response rather than the adaptive immune response 
induced by the vaccine.
Duration of Follow-up for Mortality Rate Outcome
The SGMVD proposed that the duration of follow-up ef-
forts should be sufficient to compare the efficacy between 
the candidates. The steering group suggested a follow-up 
period of at least 28 days after challenge.
Areas Requiring Further Advancement
Animal Melioidosis Models Using Subcutaneous Route
Much remains to be learned regarding use of subcutaneous 
B. pseudomallei inoculation in animal models. Most of the 
animal models developed in the past used intraperitoneal, 
intravenous, or inhalational B. pseudomallei inoculation; 
only a small number used a subcutaneous route (17,19–21). 
A study using goats to compare subcutaneous versus intra-
peritoneal inoculation showed that, in animals inoculated 
intraperitoneally, septicemia with multiple microabscesses 
developed throughout the body, whereas in animals inocu-
lated subcutaneously, localized abscesses developed in the 
lungs and spleen (22). It has been shown that the dose of B. 
pseudomallei required to result in a rapidly fatal infection 
administered by the subcutaneous route in mice is consider-
ably higher than that required when using the inhalational 
route (17). The Defence Science and Technology Labora-
tory (Dstl), United Kingdom, has conducted subcutaneous 
B. pseudomallei challenge in marmosets (Callithrix jacchus) 
(23), but a 50% lethal dose could not be estimated because all 
14 marmosets died within 4 days of infection when the low-
est dose of 26 CFU was used (23). The study shows that most 
marmosets challenged with subcutaneous inoculation have 
a systemic disease with occasional lung involvement (23).
Diabetic Murine Model
A small number of diabetic mouse models have been 
evaluated with B. pseudomallei infection, but none of the 
candidate vaccines have been evaluated in diabetic mice. 
Although streptozotocin-induced diabetic mice have 
been used to study a range of diseases, in 1996, Brett and 
Woods reported that adult streptozotocin-induced diabetic 
Sprague-Dawley rats were not susceptible to intraperitone-
al challenge with B. pseudomallei (24). In 2011, Hodgson 
et al. reported the use of 8-week-old BKS.Cg-Dock7m +/+ 
Leprdb/J mice that carried a genetic mutation in the leptin 
receptor (db/db) and become insulin resistant, diabetic, and 
hyperglycemic (24). The study showed that diabetic mice 
died more rapidly than nondiabetic mice after subcutane-
ous challenge with B. pseudomallei and that macrophages 
from diabetic mice were unable to contain and kill B. pseu-
domallei (20). In 2013, Hodson et al. compared C57BL/6J-
Dock7m Leprdb/++ mice to diet-induced C57BL/6 diabetic 
mice and found that the metabolic profiles of the 2 models 
were not different. The study also showed that diet-induced 
diabetic mice died more rapidly than did nondiabetic mice 
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after subcutaneous challenge with B. pseudomallei and that 
cytokine responses were impaired in the diabetic mice (21). 
It has been suggested that diet-induced C57BL/6 diabetic 
mice might be better models than diabetic homozygotes 
because db/db mice exhibit additional immune dysfunc-
tions when compared to type 2 diabetic mice induced by 
a high-fat diet (21). Nonetheless, several other current and 
upcoming mouse models use more sophisticated strategies 
for gene inactivation that more closely replicate insulin re-
sistance in type 2 diabetes (25). Further studies are needed 
to determine which diabetic mouse model is the most ap-
propriate model of melioidosis in humans with diabetes 
and to evaluate potential candidate vaccines in that model.
Nonhuman Primate Model
It is currently unclear which NHP model is the most suit-
able for melioidosis vaccine evaluation. Only the marmoset 
has been evaluated by using a B. pseudomallei subcutaneous 
inoculation route (23). On the basis of data obtained in meli-
oidosis inhalation models, the marmoset appears to be the 
most susceptible NHP; the rhesus macaque (Macaca mulat-
ta) is of intermediate susceptibility (26), and the cynomolgus 
macaque (M. fascicularis) is the most resistant to B. pseudo-
mallei inoculation (unpub. data). The African green monkey 
(Chlorocebus aethiops) is reported to be comparable to the 
rhesus macaque in terms of susceptibility to B. pseudomallei 
when inoculated by using the inhalation route (27). Further 
studies are needed to determine which NHP model is the 
most representative of human melioidosis and will be most 
useful for evaluation of candidate vaccines.
Immunity among Persons with Diabetes
Immunity and response to vaccines in humans with dia-
betes requires further study. In the cases of influenza and 
hepatitis B vaccines, persons who have diabetes have com-
parable responses to those who do not, and persons with 
diabetes acquire protection against these viruses (28–31). 
Effectiveness of pneumococcal vaccines is also observed 
in persons with diabetes, particularly in preventing pneu-
mococcal bacteremia (32,33). However, the immune defi-
cit leading to susceptibility to melioidosis in persons with 
diabetes has not been clearly established. The mechanisms 
of immune protection against melioidosis are complex and 
involve both innate and adaptive immunity (3). An under-
standing of immunologic responses among persons with 
diabetes against melioidosis and correlates of protection 
would inform the development of a melioidosis vaccine 
that protects against natural infection.
Funding for Head-to-Head Comparison and  
Future Objectives of SGMVD
The SGMVD will seek funding from multiple sources for 
the head-to-head comparison of candidate vaccines at an 
independent institute. The SGMVD aims to communicate by 
using email, meet yearly to steer the process of vaccine de-
velopment, continue to identify knowledge gaps on vaccine 
development, and ensure that the head-to-head comparison 
is implemented and conducted within a timely fashion.
Potential of Phase I, II and III Clinical Studies
Using the stage-gating approach, the SGMVD will develop 
robust criteria for advancing vaccine candidates from the 
NHP model stage to the phase I, II, and III clinical studies. 
SGMVD will also consider vaccine candidates developed 
for biodefense purposes if any are found to be effective by 
other groups, including Defense Threat Reduction Agency, 
National Institute of Allergy and Infectious Disease, and 
BARDA. On the basis of preliminary discussions, candi-
date vaccines that pass the first head-to-head comparison 
in 2 different mouse models and a further diabetic mouse 
model should go forward to be evaluated in a NHP model. 
The SGMVD does not consider that a diabetic NHP model 
is required. The first phase I and phase II human clinical 
studies should initially be conducted in healthy volunteers 
to determine safety and immunogenicity of vaccines, and 
promising candidates should be examined in phase I and 
phase II clinical studies that include persons with diabetes.
Conclusions
The SGMVD has recognized the need for the head-to-head 
comparison of candidate vaccines in standardized mouse 
models using a defined set of criteria and an independent 
institute to evaluate melioidosis candidate vaccines for ad-
vancement to the NHP model stage. None of the animal 
models will be a perfect reflection of human infection; the 
main purpose of using mouse and NHP models is to care-
fully select the optimal candidate vaccines for future clini-
cal studies by using a gating process approach.
The ultimate aim of the SGMVD is to facilitate the pro-
duction of a vaccine to protect against naturally acquired 
infection, with potential to be used in high-risk groups such 
as persons with diabetes in areas to which melioidosis is 
endemic, such as northeast Thailand. The SGMVD has 
identified knowledge gaps in the process of advancing mel-
ioidosis vaccines to the point of early phase clinical stud-
ies. The SGMVD will also continue to seek advice from 
experts in related fields over time, including those with 
expertise in vaccine development and testing, animal mod-
els (20,21), and bacterial genomics. This committee aims 
to hasten the processes required to obtain a cost-effective, 
safe, and licensed vaccine against melioidosis.
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